Hasan Abdullah Özkan, CEO the Turkish headquartered company, notes that Sunar Misir is committed to innovation and developing value added ingredients based upon rising consumer demand for healthy products.
As a result of aging populations, extended lifespans, and socioeconomic changes around the world, health services is one of the most important issues of the 21st century. In relation to that, global pharmaceutical revenues increased to over US$1 trillion. Considering these factors, innovative drugs and new treatments will become crucial in this market environment. “Through our chain of expertise, including Sunar Mısır Research and Development Center and technical sales and business development team, we are eyeing high penetration in the local and global pharma market. We’ve identified key target countries for the pharma business and Turkey is one of them since the market is promising and grew by 16.5 percent in 2016,” Özkan underlines.
The plant is capable of processing different types of ultra-pure polyols, each answering specific customer demands. Thanks to its excellent purification process, the performance of sorbitol and maltitol in final products and processes, will be quite satisfying. The facility was designed to produce pharma grade, food grade and industry grade products in liquid, crystalline and powder forms fulfilling the requirements of GMP (Good Manufacturing Practice) certificate. Besides, Sunar Mısır R&D Center is close to finalizing the development stage of new polyols and launches planned for 2019.
Özkan highlights Sunar Mısır’s ambitions to become a major player in the global polyol market with 100,000 tons of annual production capacity and bold future plans in the category. This investment also illustrates Sunar Mısır’s commitment to the economic progress in Turkey through job growth and financial contributions, he concludes.